Crescent Biopharma (CBIO) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 17.1% versus a loss of 35.5%. Over five years, PHAT leads with a -78.1% price change compared with -92.9% for CBIO. Phathom Pharmaceuticals is the larger company by market cap ($586.5 million vs $553.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | PHAT |
|---|---|---|
| Share price | $14.91 | $7.25 |
| Market cap | $553.86M | $586.53M |
| 1-day change | +5.59% | +1.68% |
| YTD return | +19.06% | -57.02% |
| 1-year return | +17.08% | -35.48% |
| 5-year return | -92.87% | -78.07% |
| Forward P/E | — | 6.73 |
| EPS (TTM) | $-7.63 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $18.31 |
| 52-week low | $8.72 | $6.52 |
| Distance from 52-week high | -45.60% | -60.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.27% | +182.07% |
| Average volume | 399.18K | 1.38M |
| Shares outstanding | 37.14M | 80.90M |
| Employees | 69 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed PHAT by 52.6 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
CBIO vs PHAT FAQ
Which is bigger, Crescent Biopharma or Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $586.53M compared with $553.86M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or PHAT?
CBIO returned +17.08% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.